MAY 2 2 2003 W

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of HABERMANN, et al.

Examiner:
Art Unit:

1614

Application No.: 10/065,994

Filed: 12/09/2002

PYRIDINE-2,4-DICARBOXYLIC ACID

DIAMIDES AND PYRIMIDINE-4,6-DICARBOXYLIC ACID DIAMIDES AND THE USE THEREOF FOR SELECTIVELY INHIBITING

COLLAGENASES

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

Date of Deposit

Signature

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Patent Application Commissioner of Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

Title:

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

(b)	This	Information Disclosure Statement is filed after the period set forth in 37 C.F.R.						
	1.97(b), but is believed to be filed before the mailing date of a final action under							
	or a	notice of allowance under §1.311, whichever occurs first.						
	(1)	The undersigned attorney certifies that each item of information contained in this						
		Information Disclosure Statement was cited in a communication from a foreign						
		patent office in a counterpart foreign application not more than three months prior						
		to the filing of this statement;						
	(2)	The undersigned attorney certifies that no item of information contained in this						
		Information Disclosure Statement was cited in a communication from a foreign						
		patent office in a counterpart foreign application or, to the knowledge of the						
		undersigned attorney after making reasonable inquiry, was known to any						
		individual designated in §1.56(c) more than three months prior to the filing of this						
		statement; or						
	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in						
		which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is						
		authorized.						

Respectfully submitted,

George G. Wang, Reg. No. 41,419 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2843

Telefax (908) 231-2626

Aventis Docket No. DEAV2001/0073 US NP

MAY 2 2 2003 and	e type a plus sign (+) inside this box the Paperwork Reduction Act of 1995, no persons are required to res	Patent spond to a collection
The state of the s	Substitute for form 1449A/PTO	Application N
PADEMARK	INFORMATION DISCLOSURE	Filing Date

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
and Trademark Office: U.S. DEPARTMENT OF COMMERCE
of information unless it contains a valid OMB control number.

NE	ORM	ATION	DISC	OSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

2 Sheet 1 of

Compl t if Kn wn						
Application Number	10/065,994					
Filing Date	12-09-2002					
First Named Inventor	WEITHMANN					
Group Art Unit						
Examiner Name						
Attorney Docket Number	DEAV2001/0073 US NP					

LLC DATENT DOCUMENTS										
	U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No.¹	U.S. Paten Number	t Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
						<i>X</i>				
						C. T. C.				
						Q 2 /				
						7, 7, 0				
			++							
		-				-00				
		<u> </u>	+							
						- 448-444				
			1 1		1					

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Docu Office ³ Number ⁴		cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶		
		EΡ	0418797		BAADER	08-24-1994				
		ΕP	0463592		BAADER	08-17-1994				
		EΡ	0606046B1		MACPHERSON	10-08-1997	-			
		wo	02/064568A1		BARVIAN	08-22-2002				
		wo	02/064571A1		BARVIAN	08-22-2002				
		wo	94/28889		LANSBURY	12-22-1994				
I								Ш		
		_			-			\vdash		
						 		\vdash		

Examiner	Date	
Signature	Conside	red

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	us sign (+) inside this 2 2003 H			Patent and Tradem	PTO/SB/08B (10-96 oroved for use through 10/31/99. OMB 0651-003 ark Office: U.S. DEPARTMENT OF COMMERC on unless it contains a valid OMB contract of the contr	
Substitu	ite for foot 1449B/PT	го		С	mplet if Known	语 C
ZZAD	MARIE		ISCLOSURE	Application Number	10/065,994	
INFO	DRMATIO	NE	ISCLOSURE	Filing Date	12-09-2002	J 3 2
I STA	TEMENT	BY	APPLICANT	First Named Inventor	WEITHMANN	न द
1 0.7			7.11 1 2107.1111	Group Art Unit		
	(use as many	sheet	's as necessary)	Examiner Name		事 。
Sheet	2	of	2	Attorney Docket Number	DEAV2001/0073 US NP	漫
						3

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Examiner Initials	Cite No. ¹	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MASSOVA, I. et al., Matrix Metalloproteinases: Structures, Evolution, and Diversification, The FASEB Journal, 1998, (12), pp. 1075-1095	
		VEB Deutscher Verlag der Wissenschaften, Methodenregister, Organikum, Organisch Chemisches Grundpraktikum, 15. Aufl., 1976, pg. 822	
		WEITHMANN, K.U. et al., Effects of Tiaprofenic Acid on Urinary Pyridinium Crosslinks in Adjuvant Arthritic Rats: Comparison with Doxycycline, Inflammation Research, 1997, (46), pp. 246-252	
_			
Examine Signature		Date	

Signature Considered	Examiner	Date	-
	Signature	 Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.